Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome.

N Engl J MedSep 24, 2026
Clinical ResearchHematologyMedical Genetics

Francesca Ferrua, Sabina Cenciarelli, Stefania Giannelli et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter clinical trial evaluated the safety and efficacy of etuvetidigene autotemcel (etu-cel) in patients with Wiskott-Aldrich syndrome, integrating data from two studies and an expanded-access program. With a median follow-up of 5.7 years, overall survival was 96% at both 1 and 5 years. Severe infections decreased from 2.00 to 0.15 per person-year after treatment.

Key findings

  • Overall survival was 96% at both 1 year and 5 years post-treatment.
  • Severe infections decreased from 2.00 to 0.15 per person-year after gene therapy.
  • Moderate or severe bleeding events decreased from 2.00 to 0.80 per person-year after treatment.
  • No evidence of insertional oncogenesis was observed.

Why it matters

The findings suggest that etu-cel may provide a significant clinical benefit for patients with Wiskott-Aldrich syndrome, reducing severe infections and bleeding events, which are critical complications of the disease.

Source

PubMed · PMID 42777242

Published in N Engl J Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.